The size of Panzem molecules is not the issue. The new formulation is designed to get more of it into the bloodstream, without being broken down in the intestines (small particle size makes absorption quicker). Keeping it in circulation longer is a good idea, however.
Also, we have two targets with Panzem: The blood vessels that feed tumors, and the tumors themselves. In all the dense prose posted here (unless I've missed something), I don't think anybody's ever been worried about getting to either destination (though dosage time over the target, in those 6 hours between doses, has our rapt attention as a possible issue).
Regards to all.
News 
Market Data 
Discover 
AI
